Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

937

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Aripiprazole depot 300 or 400 mg
DRUG: Aripiprazole 10-30 mg orally
DRUG: Aripiprazole depot 25 or 50 mg
DRUG: Placebo depot
DRUG: Placebo tablets

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.